

Remarks

Amendments to the description are provided that delete all references to Figures 12 and 13, which were not included in the application-as-filed. As a result of deleting those references in the text, further amendments were made to correctly assign the citations of the remaining figures in the body of the text to the corresponding figures in the drawings.

The Claims 1 - 3, 6 - 10, 18 - 21, 61 and 62 have been canceled without disclaimer and new claims 99 - 126 have been added. The new claims 99 - 126 contain no new matter, since they are fully supported by the specification.

Support for the claims that are drawn to isolated antibodies and their method of production, i.e., claims 99 - 102, is found at least at page 59, lines 15 - 20, page 60, lines 7 - 26, and pages 91 - 92.

Support for the claims that point out specific sequences to which the antibodies are directed, i.e., claims 99, 106, 116 and 117, is found at least at page 7, lines 18 - 21 and page 24, lines 12 - 15.

Support for the claims that are drawn to antigens comprising various peptides, oligopeptides, and GDNF-family conserved peptides, i.e., claims 103 - 106, is found at least on page 59, lines 21 - 31, and page 93, line 28 - page 95, line 3.

Support for the claims that are drawn to methods of detecting neurturin or neurulin family members in a sample and to methods of determining antibody to antigen binding, i.e., claims 107 - 126 is found at least at page 58, lines 4 - 17 and page 58, line 29 - page 59, line 3 and page 92, lines 11 - 15.

Applicants respectfully request that the herein-mentioned amendments and remarks be entered into the case. Should any questions arise or if Applicants' attorney can facilitate the prosecution of this case in any way, it is requested that the undersigned attorney be contacted.

Respectfully submitted,


Elie H. Grullon
Reg. No. 44,704
Howell & Haferkamp, L.C.
7733 Forsyth Boulevard, Suite 1400
St. Louis, Missouri 63105
(314) 727-5188

February 22, 2001